115 related articles for article (PubMed ID: 37852547)
1. RNF13 protects against pathological cardiac hypertrophy through p62-NRF2 pathway.
Guo S; Zhang BB; Gao L; Yu XY; Shen JH; Yang F; Zhang WC; Jin YG; Li G; Wang YG; Han ZY; Liu Y
Free Radic Biol Med; 2023 Nov; 209(Pt 2):252-264. PubMed ID: 37852547
[TBL] [Abstract][Full Text] [Related]
2. Targeting E3 Ubiquitin Ligase WWP1 Prevents Cardiac Hypertrophy Through Destabilizing DVL2 via Inhibition of K27-Linked Ubiquitination.
Zhao D; Zhong G; Li J; Pan J; Zhao Y; Song H; Sun W; Jin X; Li Y; Du R; Nie J; Liu T; Zheng J; Jia Y; Liu Z; Liu W; Yuan X; Liu Z; Song J; Kan G; Li Y; Liu C; Gao X; Xing W; Chang YZ; Li Y; Ling S
Circulation; 2021 Aug; 144(9):694-711. PubMed ID: 34139860
[TBL] [Abstract][Full Text] [Related]
3. Diosmetin Protects against Cardiac Hypertrophy via p62/Keap1/Nrf2 Signaling Pathway.
Guo Y; Li D; Cen XF; Qiu HL; Ma YL; Liu Y; Huang SH; Liu LB; Xu M; Tang QZ
Oxid Med Cell Longev; 2022; 2022():8367997. PubMed ID: 35242278
[TBL] [Abstract][Full Text] [Related]
4. The E3 Ligase TRIM16 Is a Key Suppressor of Pathological Cardiac Hypertrophy.
Liu J; Li W; Deng KQ; Tian S; Liu H; Shi H; Fang Q; Liu Z; Chen Z; Tian T; Gan S; Hu F; Hu M; Cheng X; Ji YX; Zhang P; She ZG; Zhang XJ; Chen S; Cai J; Li H
Circ Res; 2022 May; 130(10):1586-1600. PubMed ID: 35437018
[TBL] [Abstract][Full Text] [Related]
5. RNF207 exacerbates pathological cardiac hypertrophy via post-translational modification of TAB1.
Yuan L; Bu S; Du M; Wang Y; Ju C; Huang D; Xu W; Tan X; Liang M; Deng S; Yang L; Huang K
Cardiovasc Res; 2023 Mar; 119(1):183-194. PubMed ID: 35352799
[TBL] [Abstract][Full Text] [Related]
6. Peroxiredoxin-1 ameliorates pressure overload-induced cardiac hypertrophy and fibrosis.
Tang C; Yin G; Huang C; Wang H; Gao J; Luo J; Zhang Z; Wang J; Hong J; Chai X
Biomed Pharmacother; 2020 Sep; 129():110357. PubMed ID: 32531679
[TBL] [Abstract][Full Text] [Related]
7. Nrf2 protects against maladaptive cardiac responses to hemodynamic stress.
Li J; Ichikawa T; Villacorta L; Janicki JS; Brower GL; Yamamoto M; Cui T
Arterioscler Thromb Vasc Biol; 2009 Nov; 29(11):1843-50. PubMed ID: 19592468
[TBL] [Abstract][Full Text] [Related]
8. C1q-TNF-related protein-3 attenuates pressure overload-induced cardiac hypertrophy by suppressing the p38/CREB pathway and p38-induced ER stress.
Zhang B; Zhang P; Tan Y; Feng P; Zhang Z; Liang H; Duan W; Jin Z; Wang X; Liu J; Gao E; Yu S; Yi D; Sun Y; Yi W
Cell Death Dis; 2019 Jul; 10(7):520. PubMed ID: 31285424
[TBL] [Abstract][Full Text] [Related]
9. Myricetin Alleviates Pathological Cardiac Hypertrophy via TRAF6/TAK1/MAPK and Nrf2 Signaling Pathway.
Liao HH; Zhang N; Meng YY; Feng H; Yang JJ; Li WJ; Chen S; Wu HM; Deng W; Tang QZ
Oxid Med Cell Longev; 2019; 2019():6304058. PubMed ID: 31885808
[TBL] [Abstract][Full Text] [Related]
10. Nrf2 enhances myocardial clearance of toxic ubiquitinated proteins.
Wang W; Li S; Wang H; Li B; Shao L; Lai Y; Horvath G; Wang Q; Yamamoto M; Janicki JS; Wang XL; Tang D; Cui T
J Mol Cell Cardiol; 2014 Jul; 72():305-15. PubMed ID: 24747945
[TBL] [Abstract][Full Text] [Related]
11. Muscle-specific RING finger 1 negatively regulates pathological cardiac hypertrophy through downregulation of calcineurin A.
Maejima Y; Usui S; Zhai P; Takamura M; Kaneko S; Zablocki D; Yokota M; Isobe M; Sadoshima J
Circ Heart Fail; 2014 May; 7(3):479-90. PubMed ID: 24526353
[TBL] [Abstract][Full Text] [Related]
12. Deubiquitinating enzyme CYLD mediates pressure overload-induced cardiac maladaptive remodeling and dysfunction via downregulating Nrf2.
Wang H; Lai Y; Mathis BJ; Wang W; Li S; Qu C; Li B; Shao L; Song H; Janicki JS; Sun SC; Wang XL; Tang D; Cui T
J Mol Cell Cardiol; 2015 Jul; 84():143-53. PubMed ID: 25935309
[TBL] [Abstract][Full Text] [Related]
13. HINT1 (Histidine Triad Nucleotide-Binding Protein 1) Attenuates Cardiac Hypertrophy Via Suppressing HOXA5 (Homeobox A5) Expression.
Zhang Y; Da Q; Cao S; Yan K; Shi Z; Miao Q; Li C; Hu L; Sun S; Wu W; Wu L; Chen F; Wang L; Gao Y; Huang Z; Shao Y; Chen H; Wei Y; Chen F; Han Y; Xie L; Ji Y
Circulation; 2021 Aug; 144(8):638-654. PubMed ID: 34098726
[TBL] [Abstract][Full Text] [Related]
14. DEF6(differentially exprehomolog) exacerbates pathological cardiac hypertrophy via RAC1.
Sun Y; Xu C; Jiang Z; Jiang X
Cell Death Dis; 2023 Jul; 14(7):483. PubMed ID: 37524688
[TBL] [Abstract][Full Text] [Related]
15. HECT (Homologous to the E6-AP Carboxyl Terminus)-Type Ubiquitin E3 Ligase ITCH Attenuates Cardiac Hypertrophy by Suppressing the Wnt/β-Catenin Signaling Pathway.
Goto J; Otaki Y; Watanabe T; Kobayashi Y; Aono T; Watanabe K; Wanezaki M; Kutsuzawa D; Kato S; Tamura H; Nishiyama S; Arimoto T; Takahashi H; Shishido T; Watanabe M
Hypertension; 2020 Dec; 76(6):1868-1878. PubMed ID: 33131309
[TBL] [Abstract][Full Text] [Related]
16. Triterpenoid dihydro-CDDO-trifluoroethyl amide protects against maladaptive cardiac remodeling and dysfunction in mice: a critical role of Nrf2.
Xing Y; Niu T; Wang W; Li J; Li S; Janicki JS; Ruiz S; Meyer CJ; Wang XL; Tang D; Zhao Y; Cui T
PLoS One; 2012; 7(9):e44899. PubMed ID: 23028668
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitin-specific protease 19 blunts pathological cardiac hypertrophy via inhibition of the TAK1-dependent pathway.
Miao R; Lu Y; He X; Liu X; Chen Z; Wang J
J Cell Mol Med; 2020 Sep; 24(18):10946-10957. PubMed ID: 32798288
[TBL] [Abstract][Full Text] [Related]
18. The alteration of protein prenylation induces cardiomyocyte hypertrophy through Rheb-mTORC1 signalling and leads to chronic heart failure.
Xu N; Guan S; Chen Z; Yu Y; Xie J; Pan FY; Zhao NW; Liu L; Yang ZZ; Gao X; Xu B; Li CJ
J Pathol; 2015 Apr; 235(5):672-85. PubMed ID: 25385233
[TBL] [Abstract][Full Text] [Related]
19. Cardiac-specific BACH1 ablation attenuates pathological cardiac hypertrophy by inhibiting the Ang II type 1 receptor expression and the Ca2+/CaMKII pathway.
Wei X; Jin J; Wu J; He Y; Guo J; Yang Z; Chen L; Hu K; Li L; Jia M; Li Q; Lv X; Ge F; Ma S; Wu H; Zhi X; Wang X; Jiang L; Osto E; Zhang J; Meng D
Cardiovasc Res; 2023 Aug; 119(9):1842-1855. PubMed ID: 37279500
[TBL] [Abstract][Full Text] [Related]
20. Aldolase promotes the development of cardiac hypertrophy by targeting AMPK signaling.
Li Y; Zhang D; Kong L; Shi H; Tian X; Gao L; Liu Y; Wu L; Du B; Huang Z; Liang C; Wang Z; Yao R; Zhang Y
Exp Cell Res; 2018 Sep; 370(1):78-86. PubMed ID: 29902536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
